Bio-Based Fiber Interface Engineering Patents: Leaders & Trends 2026
- Filing peaked in 2018 at 13 records and has not returned to that level since, with the 2022 midpoint showing zero — a flat-to-declining trend rather than an emerging one.
- The field spans eight IPC subclasses from dyeing and printing (D06P) to implants (A61F) and laminates (B32B), meaning interface-engineering claims are scattered across textile, medical and materials-science classifications rather than concentrated in one.
- The most-cited records cluster around two families on catalytic nanoparticle embedding and functional biomaterial coatings, both filed originally in the US and later extended via WO — a signal of where prior art is thickest.
What bio-based fiber interface engineering covers
This landscape tracks patent families addressing the interface between bio-based or biopolymer fibers and a surrounding matrix — the surface chemistry, coating, plasma or chemical treatment, and bonding architecture that determines whether a fiber reinforces a composite, integrates with tissue, or holds a dye or finish. The search spans both textile-industry framing (fiber-matrix interface, surface modification) and materials-science framing (interfacial adhesion), which is why the resulting IPC mix runs from dyeing equipment to surgical implants.
With 48 total families across an eleven-year window, this is a compact, technically specific niche rather than a mass-filing category. That makes ranking position and citation concentration more informative than raw volume: a handful of families account for a disproportionate share of forward citations, and the assignee list has no single dominant filer running away with the space.
Filing trend and technology composition
Publication counts below are drawn directly from the 48 families in this dataset. Because publication lags filing by roughly 18 months, the most recent one to two years will always understate true filing activity — read the tail of any trend line with that in mind.
A single peak, then a flat tail
Annual filings rose to a peak of 13 in 2018 and fell back toward zero by the 2022 midpoint, with 2026 not yet showing new activity. That pattern is consistent with a technology that had one active filing wave rather than sustained, compounding interest — worth checking against citation data before assuming the field has gone quiet.
Eight subclasses, no single center of gravity
D06P (dyeing and printing, 12 records) and A61F (implants and prostheses, 11 records) lead, followed closely by B32B (laminates, 10) and A61L (sterilising, 9). C07K (peptides), D02G (yarn texturing), D01D (filament spinning) and B01J (catalysis) each contribute a smaller but non-trivial share — evidence that interface engineering here is being solved from at least three distinct engineering traditions: textile finishing, biomedical implants, and composite layering.
Shares are the percentage of the 48 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Bio-Based Fiber Interface Engineering with Eureka
This page is one run against one query. Ask Eureka your own question about bio-based fiber interface engineering and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited and most recent filings
Continuous fiber-reinforced composite 3D printing consumable (US20260184017A1)
The application describes a braided-sleeve printing consumable in which a continuous fiber core is embedded inside a sheath fiber braid through encapsulation or interweaving, aimed at improving interfacial bonding force between the core and sheath fibers. The filing claims control over fiber type, ratio, braiding structure, relative position and content to tune mechanical properties of the resulting 3D-printed article.Filed by Shanghai Novastar Technology Co., Ltd., dated 2026-07-02 — the newest record in this dataset.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20200254432A1 | Enhanced catalytic materials with partially embedded catalytic nanoparticles | 44 |
| 2 | US20160250831A1 | Functional biomaterial coatings for textiles and other substrates | 37 |
| 3 | US20190134267A1 | Biopolymer scaffold implants and methods for their production | 35 |
| 4 | WO2019068110A1 | Enhanced catalytic materials with partially embedded catalytic nanoparticles | 29 |
| 5 | WO2015061079A1 | Functional biomaterial coatings for textiles and other substrates | 16 |
| 6 | WO2019084209A1 | Biopolymer scaffold implants and methods for their production | 15 |
| 7 | WO2008085139A1 | Apparatus and method for treatment of wood, wood fibres and wood-based materials | 12 |
| 8 | US10653817B2 | Method for producing an implantable ligament and tendon repair device | 10 |
| 9 | WO2015088920A1 | Plasma treatments for coloration of textiles | 9 |
| 10 | US20190365953A1 | Wavy multi-component vascular grafts with biomimetic mechanical properties, antithrombogenicity, and endothel… | 8 |
Citation counts are drawn from the searched corpus only and favour older filings; treat them as a signal of technical influence, not of what is most current.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the citation and filing data actually shows
Three patterns stand out once the assignee ranking and citation table are read together: filing has cooled from an early peak, citation weight sits on a small number of older families, and the receiving-office split shows this is a US- and Europe-anchored field.
One filing wave, not sustained growth
Annual filings rose to 13 in 2018 then declined toward zero by 2022, with no rebound visible through the 2026 cut-off. That is the profile of a technology that had a concentrated early push rather than compounding year-over-year interest.
Two families carry most of the citation weight
The catalytic-nanoparticle-embedding family (US20200254432A1, 44 citations, extended via WO2019068110A1 at 29) and the functional biomaterial coating family (US20160250831A1, 37 citations, extended via WO2015061079A1 at 16) between them account for the bulk of forward citations in this dataset.
Filing is concentrated in the US and Europe
United States (17) and European Patent Office (13) filings dominate the receiving-office split, with WIPO/PCT (6) and smaller counts in Austria, Australia and Germany. This is not a jurisdiction where China-first filing patterns are visible in this dataset.
Collaboration is limited and academic
Only three co-assignee pairs appear in the dataset, and the strongest links are between a university mathematics/physics/informatics faculty and two individual inventors — a plasma-surface-treatment research group rather than an industrial joint venture.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to bio-based fiber interface engineering, with the prior art for and against each one.
Assignee landscape and momentum
No single assignee dominates this 48-family dataset. The recent-year momentum table shows every tracked assignee, including the most recent filer, at zero activity in the latest year — consistent with the broader flat-to-declining trend rather than a signal specific to any one company.
Activity has stalled across the board
Every assignee in the recent-momentum table, from Embody Inc to The North Face to Shanghai Novastar Technology, shows zero filings in the most recent tracked year, with Shanghai Novastar down -100% year-over-year from its prior activity.
Academic and research assignees are well represented
Harvard's President and Fellows, the Wisconsin Alumni Research Foundation, and a Slovak university's mathematics/physics/informatics faculty all appear among tracked assignees, pointing to research-driven rather than purely commercial origins for a meaningful share of filings.
Apparel and materials companies sit alongside implant specialists
The North Face and Embody Inc appear alongside implant- and biomaterial-focused entities, reflecting the dataset's split between textile/apparel applications and biomedical fiber-matrix work.
| Assignee | Recent year | YoY |
|---|---|---|
| The North Face | 0 | — |
| EMBODY INC | 0 | — |
| President and Fellows of Harvard College | 0 | — |
| Comenius University Faculty of Mathematics, Physics and Informatics | 0 | — |
| Wisconsin Alumni Research Foundation | 0 | — |
| SHANGHAI NOVASTAR TECHNOLOGY CO LTD | 0 | -100% |
| RAHEL JOZEF | 0 | — |
| CERNAK MIRKO | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, licensing, or identifying a filing gap.
Check the two highest-cited families before drafting
Any new filing touching catalytic nanoparticle embedding or functional biomaterial coatings should be checked against both the US priority filings and their WO extensions, since these carry the heaviest citation weight in the corpus.
Explore citation trees in EurekaMap the under-claimed branches against your own pipeline
Plasma-based surface activation and peptide-mediated bonding show thinner filing density than the dyeing and implant clusters — worth a targeted search before assuming the space is open.
Run a white-space search in EurekaWatch for renewed filing activity
With every tracked assignee at zero in the latest year, a rebound in filings from any of the academic or commercial assignees here would be an early signal worth monitoring given the historical 2018 peak.
Set up assignee alerts in EurekaCommon questions about this landscape
It covers patent families that address the boundary between a bio-based or biopolymer fiber and whatever it is bonded to, coated onto, or embedded in — a composite matrix, a dye, a coating, or human tissue in the case of implants. This search combines fiber-material terms (bio-based fiber, biobased fiber, biopolymer fiber) with interface terms (fiber-matrix interface, surface modification, interfacial adhesion). Because both sets of terms are used across textile, biomedical and materials-science filings, the resulting IPC spread crosses eight distinct subclasses rather than sitting in one.
The dataset of 48 families shows no single runaway leader; instead there is a mix of commercial apparel and biomaterial companies alongside academic and research-foundation assignees such as Harvard's President and Fellows and the Wisconsin Alumni Research Foundation. Every tracked assignee, including the most recently active filer, shows zero filings in the latest tracked year, which is consistent with the broader flat-to-declining trend rather than any one company pulling back specifically. Anyone evaluating competitive position should look at the full assignee ranking table rather than assume a market leader exists here.
The trend data shows annual filings rising to 13 in 2018, then falling toward zero by the 2022 midpoint and remaining low through the 2026 cut-off. This pattern is more typical of a technology that saw one concentrated wave of interest — possibly tied to a specific research push or product cycle — rather than a steadily compounding field. It is worth remembering that publication lags filing by roughly 18 months, so the most recent one to two years in any trend will understate true activity; even so, the decline from the 2018 peak predates that lag window and looks structural rather than an artifact of reporting delay.
Two families carry most of the forward-citation weight in this corpus: one covering catalytic materials with partially embedded nanoparticles (44 citations on its US filing, extended via a WO filing with 29), and one covering functional biomaterial coatings for textiles and other substrates (37 citations on its US filing, extended via a WO filing with 16). High citation counts inside a searched corpus tend to favour older filings simply because they have had more time to be cited, so these numbers should be read as a signal of technical influence rather than of current commercial importance.
Relative to the denser dyeing, implant and laminate clusters, sub-areas like plasma-based fiber surface activation, peptide-mediated fiber-matrix bonding, and continuous-fiber braided-sleeve composite architectures show thinner filing density in this dataset. That does not guarantee an open field — a targeted freedom-to-operate search is still necessary — but it does mean a well-drafted first claim in these branches faces less crowded prior art than one filed directly against the dyeing or implant clusters where filing density is highest.
Research Bio-Based Fiber Interface Engineering in depth with Eureka
Go past this page: query the whole bio-based fiber interface engineering corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.